Buprenorphine (Suboxone, Sublocade, Zubsolv)

What it treats

Buprenorphine is approved by the U.S. Food and Drug Administration for opioid use disorder. Some formulations are also approved for chronic pain, but this page focuses on the use disorder indication.

It's considered a first-line medication for opioid use disorder alongside methadone. Guidelines (ASAM, SAMHSA, WHO) support long-term treatment as the standard, not a short taper. Under the Consolidated Appropriations Act of 2023, the DATA-waiver ("X-waiver") is no longer required in the U.S. Any prescriber with a standard DEA registration can prescribe it.

How it works

Buprenorphine binds tightly to the µ-opioid receptor and turns it on only partially. That partial activation is enough to stop cravings and withdrawal, but not enough (at usual doses) to produce a strong high. The tight binding also displaces other opioids from the receptor and blocks them from binding, which is why full opioids feel much weaker on top of buprenorphine.

The partial-agonist ceiling means respiratory depression flattens out at higher doses. It doesn't scale up the way it does with full agonists. That's the main safety story.

The naloxone in Suboxone and Zubsolv is there to discourage crushing and injecting the pill. Taken as directed (dissolved under the tongue), the naloxone isn't absorbed meaningfully. Injected, naloxone hits the receptor and produces withdrawal.

Receptor mechanism (detail)

Buprenorphine is a high-affinity partial agonist at the µ-opioid receptor with antagonist activity at the κ-opioid receptor and additional binding at δ and nociceptin receptors. The partial-agonist ceiling limits respiratory depression at higher doses. The κ antagonism may contribute to mood effects that some patients notice.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual.

Sublingual induction (Suboxone, Zubsolv, generics). After the person is in mild-to-moderate withdrawal (typically COWS around 8 to 12), a first dose of 2 to 4 mg is given, with additional doses over the first day to reach 8 to 16 mg. The target maintenance dose is often 8 to 24 mg per day. Some patients need higher.

Timing before induction. To avoid precipitated withdrawal, a gap after the last opioid is needed: usually 12 to 24 hours after short-acting opioids, 24 to 72 hours after long-acting opioids, and 48 to 72 hours or more after methadone. Fentanyl often needs longer than the classic guidance suggests. Micro-induction protocols are increasingly common when fentanyl is on board.

Sublocade (extended-release subcutaneous). After the person is stable on 8 to 24 mg of sublingual buprenorphine for at least a week, Sublocade is given as 300 mg SC monthly for the first 2 months, then 100 mg SC monthly maintenance. Some people stay at 300 mg monthly.

Safety monitoring

• Liver function tests (LFTs). Baseline and periodically. Buprenorphine can raise transaminases, especially in people with hepatitis C.
• Respiratory depression risk. Higher when combined with benzodiazepines, alcohol, gabapentinoids, or other sedatives. Combined use isn't an absolute contraindication in opioid use disorder, but it needs a careful conversation.
• Dental problems. In 2022 the FDA added a warning about tooth decay, cavities, oral infections, and tooth loss with sublingual buprenorphine. Rinsing with water after the tablet or film dissolves, waiting at least an hour before brushing, and regular dental care all help.
• Precipitated withdrawal. The main induction risk. Careful timing and, where needed, micro-induction.
• Naloxone kit. Every patient on opioid agonist therapy should have naloxone at home.
• Adherence and diversion. State prescription drug monitoring program checks are standard.
• QT prolongation. Not a major concern at usual doses (unlike methadone), but worth noting at very high doses or with QT-prolonging combinations.

What it feels like

Early days

The first dose during induction usually settles withdrawal within 30 to 60 minutes. Some people feel a bit sedated or foggy at first; that usually eases within a few days. If precipitated withdrawal happens, symptoms come on quickly and worsen: this is a signal that the timing wasn't right or that fentanyl is involved and a different induction plan is needed.

Later weeks

On a steady dose, most people feel more or less normal. Cravings quiet. Full opioids feel weak or absent. Sleep and appetite generally settle over a few weeks. Some people notice a low, flat mood that can be part of the κ antagonism story.

Common side effects

• Constipation.
• Headache.
• Nausea, especially early.
• Sweating.
• Insomnia or vivid dreams.
• Sedation early.
• Low libido or delayed orgasm.
• Dental problems with long-term sublingual use.

Most of these are worse in the first weeks and settle. Constipation often persists.

Serious side effects and warnings

• Respiratory depression. The ceiling makes buprenorphine safer than full agonists, but combined with sedatives (benzodiazepines, alcohol, gabapentinoids) it can still cause fatal respiratory depression.
• Precipitated withdrawal. Rapid onset withdrawal if buprenorphine is given while a full agonist is still occupying the receptor. Managed with supportive care and, sometimes, higher doses of buprenorphine.
• Hepatotoxicity. Rare but reported.
• Neonatal opioid withdrawal syndrome. Expected in newborns of pregnant patients on buprenorphine. Managed with the delivery team and neonatology.
• Injection site reactions with Sublocade. Nodule, pain, redness at the depot site. Migration or intravascular injection is rare but serious.
• Dental problems. Tooth decay and infections with sublingual formulations (FDA 2022 warning).
• Serotonin syndrome. Reported in rare cases when combined with serotonergic drugs.

Sexual and relational effects

Buprenorphine can lower libido and testosterone in some men, and delay orgasm in both men and women. This is often milder than with full agonists like methadone. The relational conversation is bigger: family, partners, and recovery communities carry most of the weight of recovery, and being on a stable medication for years is now standard rather than exceptional. If sexual function shifts after starting, it's worth raising with the prescriber.

Weight, appetite, and sleep

Weight change is variable. Some people gain weight in early recovery as appetite returns; some lose. Constipation contributes to a heavy feeling. Sleep often improves after the first few weeks, though vivid dreams are common early.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual.

Induction is the key window. The timing of the last opioid, the substance involved (fentanyl vs. short-acting heroin vs. oxycodone vs. methadone), and the person's tolerance all shape the plan. Home induction protocols and clinic-based inductions are both routine. Micro-induction (starting very low doses while the person is still on a full agonist) has become common in the fentanyl era.

After induction, the maintenance dose is titrated to control craving and withdrawal without excessive sedation. Sublocade is offered once someone has been stable on sublingual dosing.

Missed doses and interactions

If a sublingual dose is missed, take it when remembered unless close to the next dose. Missing multiple days can lead to withdrawal; restarting after a longer gap is a conversation with the prescriber.

Interactions that matter:

• Benzodiazepines, alcohol, gabapentinoids, and other sedatives. Additive respiratory depression. Combined use in opioid use disorder isn't automatically disqualifying, but it's a discussion.
• CYP3A4 inhibitors and inducers. Can raise or lower buprenorphine levels. Antifungals, some HIV medications, rifampin, some anticonvulsants.
• Serotonergic drugs. Rare serotonin syndrome.
• Naltrexone. Blocks buprenorphine and precipitates withdrawal.

Give every prescriber a full medication list.

Stopping and tapering

Buprenorphine causes physical dependence, so stopping abruptly triggers withdrawal (though usually milder and longer than with short-acting opioids). Tapering over weeks to months is possible for some, but relapse rates after discontinuation are high, and long-term maintenance is the standard of care rather than an exception.

Any stopping plan should include a naloxone kit at home and a relapse-prevention plan. Loss of tolerance during a taper means an old dose of a full opioid can be fatal.

Pregnancy and breastfeeding

Buprenorphine is one of the standard options for opioid use disorder in pregnancy alongside methadone. It's compatible with breastfeeding at maintenance doses. Neonatal opioid withdrawal syndrome is expected and managed with the delivery team.

Anyone who is pregnant, planning a pregnancy, or breastfeeding should talk it through with a prescriber.

Cost and generic availability

Generic buprenorphine and buprenorphine/naloxone tablets and films are widely available and inexpensive. Sublocade is branded and expensive; manufacturer support programs and specialty pharmacies are commonly used. Insurance coverage for maintenance treatment is generally solid.

Common questions

Is this trading one addiction for another? No. Physical dependence on a stable medication that keeps someone alive and functional is different from active use disorder. Guidelines and the FDA are clear about this.

How long should I stay on it? As long as it's helping. Many people stay on buprenorphine for years or indefinitely. Trying to time-limit treatment tends to end badly.

What if I need pain medication for surgery? This needs an advance plan with the treating team. Options include continuing buprenorphine and adding other pain approaches, or a brief bridge with a full agonist. It should never be a same-day surprise.

What about my teeth? Rinse with water after the film or tablet dissolves, wait at least an hour before brushing, keep up regular dental care.

Is Sublocade better than the film? Not for everyone. The monthly shot removes the daily dose problem, which is huge for some. Others prefer the film for flexibility. Both work when used as directed.

Questions to ask your prescriber

• What are we hoping this treats, and how will we know it's working?
• How long should I plan to stay on it?
• What's the plan if I have pain or need surgery?
• Should I have naloxone at home?
• Is Sublocade an option for me down the road?

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes, and current as of June 8, 2026.

• U.S. Food and Drug Administration. Buprenorphine (Suboxone, Sublocade, Zubsolv) prescribing information. FDA 2022 warning on dental problems with sublingual buprenorphine.
• MedlinePlus, U.S. National Library of Medicine. Buprenorphine.
• DailyMed, U.S. National Library of Medicine. Buprenorphine and buprenorphine/naloxone.
• American Society of Addiction Medicine. National Practice Guideline for the Treatment of Opioid Use Disorder.
• Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder (TIP 63).